title: Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors.
abstract: Monoclonal antibodies (mAbs) have become a successful therapeutic approach in cancer. However, some patients do not achieve long-term clinical benefit and most mAbs only exert modest effects as monotherapies. Therefore, combinations with chemotherapy are currently being investigated. Emerging studies have shown a synergistic therapeutic effect of PARP inhibitors and mAbs in cancer. PARP enzymes catalytically cleave β-NAD+and transfer the ADP-ribose moiety to acceptor proteins, modifying their function. In here, we update recent data about the therapeutic effect of the combination of PARP inhibitors with mAbs in cancer treatment and discuss the molecular mechanisms involved in this synergy.
authors.affiliation: Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Department of Immunology, Hospital del Mar, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
authors.forename: José
authors.initials: J
authors.lastname: Yélamos
authors.affiliation: Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM) , Barcelona, Spain.
authors.forename: Miguel
authors.initials: M
authors.lastname: Galindo
authors.affiliation: Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM) , Barcelona, Spain.
authors.forename: Judith
authors.initials: J
authors.lastname: Navarro
authors.affiliation: Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Department of Oncology, Hospital del Mar, Barcelona, Spain.
authors.forename: Joan
authors.initials: J
authors.lastname: Albanell
authors.affiliation: Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Department of Oncology, Hospital del Mar, Barcelona, Spain.
authors.forename: Ana
authors.initials: A
authors.lastname: Rovira
authors.affiliation: Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Department of Patology, IIS Fundación Jiménez Díaz, Madrid, Spain.
authors.forename: Federico
authors.initials: F
authors.lastname: Rojo
authors.affiliation: Department of Cell Biology and Immunology; Instituto de Parasitología y Biomedicina López Neyra , Granada, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Oliver
keywords: Apo2L/TRAIL; EGFR; HER2; PARP; VEGF; monoclonal anti-body